Please login to the form below

Not currently logged in
Email:
Password:

Novartis' patupilone fails phase III trial

Novartis has announced that its investigative compound, patupilone, has failed a phase III trial of patients with advanced ovarian cancer

Novartis has announced that its investigative compound, patupilone (EPO906), has failed a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy.

The compound was tested in a phase III study carried out in around 168 sites across 22 countries. The randomised study, which involved 829 patients with epithelial ovarian, primary fallopian or primary peritoneal cancer, compared patupilone with Doxil/Caelyx (pegylated liposomal doxorubicin).

The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, safety and overall response rate. Patupilone did not show a significant overall survival advantage. Based on this, Novartis does not plan to proceed with regulatory filings based on these data.

27th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics